Hengrui Pharmaceuticals(01276.HK): Concentrated Solution for Injection HRS-8829 Receives Clinical Trial Approval Notice

NewTimeSpace News: On 15 July 2026,Hengrui Pharmaceuticals(01276.HK) issued an announcement that Beijing Shengdi Pharmaceutical Co., Ltd., its subsidiary, has received the Clinical Trial Approval Notice for Concentrated Solution for Injection HRS-8829 from the NMPA.

According to the announcement, this candidate is a small-molecule drug intended for the treatment of acute ischemic stroke. Preclinical research indicates that it can significantly improve neurological function scores, reduce cerebral infarction and cerebral edema, and inhibit the expression of inflammatory factors. Its Phase I monotherapy clinical trial is in progress. Combination therapy with edaravone, a small-molecule antioxidant, is expected to bring a new treatment option for patients.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.